PE20190378A1 - Compuestos de 2,3-dihidro-1h-indol - Google Patents
Compuestos de 2,3-dihidro-1h-indolInfo
- Publication number
- PE20190378A1 PE20190378A1 PE2018003199A PE2018003199A PE20190378A1 PE 20190378 A1 PE20190378 A1 PE 20190378A1 PE 2018003199 A PE2018003199 A PE 2018003199A PE 2018003199 A PE2018003199 A PE 2018003199A PE 20190378 A1 PE20190378 A1 PE 20190378A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- fluoro
- cancer
- dihydro
- methyl
- Prior art date
Links
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- -1 chloro, fluoromethyl Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000002524 peritoneal carcinoma Diseases 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a derivados de 2,3-dihidro-1H-indol, en donde: R1a es hidrogeno, metilo, etenilo, ciano, fluoro, cloro, fluorometilo, o difluorometilo; R1b es hidrogeno, fluoro, o cloro; R1c es hidrogeno, hidroxi, fluoro, benciloxi, entre otros; R2 es hidrogeno o metilo; R2a es hidrogeno o metilo; y R3a es tetrahidropiranilo. Entre los compuestos preferidos se tiene el siguiente: 4-fluoro-N-{(1R)}-1-[1-(tetrahidro-2H-piran-4-ilcarbonil)-2,3-dihidro-1H-indol-5-il]etil}benzamida cristalino, el cual se encuentra caracterizado por un patron de difraccion en polvo de rayos X que comprende al menos un pico a 17.38°. Estos compuestos inhiben la conversion de triptofano a cinureina y se emplean en el tratamiento de un cancer seleccionado de melanoma, leucemia mieloide aguda, leucemia linfocitica cronica, cancer colorrectal , cancer de mama , cancer de pulmon, cancer de ovario, carcinoma de trompas de Falopio, carcinoma peritoneal primario, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190378A1 true PE20190378A1 (es) | 2019-03-08 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003199A PE20190378A1 (es) | 2016-06-10 | 2017-05-31 | Compuestos de 2,3-dihidro-1h-indol |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (es) |
| EP (1) | EP3468965B1 (es) |
| JP (1) | JP6632746B2 (es) |
| KR (1) | KR102241258B1 (es) |
| CN (1) | CN109641881B (es) |
| AR (1) | AR108586A1 (es) |
| AU (1) | AU2017277833B2 (es) |
| BR (1) | BR112018072872A2 (es) |
| CA (1) | CA3027035C (es) |
| CL (1) | CL2018003543A1 (es) |
| CO (1) | CO2018013251A2 (es) |
| CR (1) | CR20180579A (es) |
| CY (1) | CY1123660T1 (es) |
| DK (1) | DK3468965T3 (es) |
| DO (1) | DOP2018000278A (es) |
| EA (1) | EA037419B1 (es) |
| EC (1) | ECSP19001734A (es) |
| ES (1) | ES2797981T3 (es) |
| HR (1) | HRP20200769T1 (es) |
| HU (1) | HUE050155T2 (es) |
| IL (1) | IL263497B (es) |
| JO (1) | JOP20170131B1 (es) |
| LT (1) | LT3468965T (es) |
| MA (1) | MA45224B1 (es) |
| MD (1) | MD3468965T2 (es) |
| ME (1) | ME03744B (es) |
| MX (1) | MX382877B (es) |
| MY (1) | MY197462A (es) |
| NZ (1) | NZ748500A (es) |
| PE (1) | PE20190378A1 (es) |
| PH (1) | PH12018502572A1 (es) |
| PL (1) | PL3468965T3 (es) |
| PT (1) | PT3468965T (es) |
| RS (1) | RS60322B1 (es) |
| SG (1) | SG11201809625RA (es) |
| SI (1) | SI3468965T1 (es) |
| TW (1) | TWI671294B (es) |
| UA (1) | UA122526C2 (es) |
| WO (1) | WO2017213919A1 (es) |
| ZA (1) | ZA201807688B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| PL3426245T3 (pl) | 2016-03-07 | 2023-05-22 | Enanta Pharmaceuticals, Inc. | Środki przeciwwirusowe zapalenia wątroby typu b |
| EP3675637A4 (en) | 2017-08-28 | 2021-05-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US12275729B2 (en) * | 2017-11-01 | 2025-04-15 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2020036837A1 (en) * | 2018-08-17 | 2020-02-20 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| AR116474A1 (es) | 2018-09-21 | 2021-05-12 | Enanta Pharm Inc | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV |
| US12065438B2 (en) | 2018-11-06 | 2024-08-20 | Merck Sharp & Dohme Llc | Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
| WO2025072355A1 (en) * | 2023-09-25 | 2025-04-03 | Biohybrid Solutions Holdings, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| WO2025140363A1 (zh) * | 2023-12-27 | 2025-07-03 | 海思科医药集团股份有限公司 | 一种苯基哌啶衍生物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2239012A3 (en) * | 2003-04-11 | 2011-06-15 | High Point Pharmaceuticals, LLC | Substituted amide derivatives and pharmaceutical uses thereof |
| ES2401482T3 (es) * | 2005-05-10 | 2013-04-22 | Incyte Corporation | Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| JP2011511800A (ja) | 2008-02-07 | 2011-04-14 | アボット・ラボラトリーズ | 正のアロステリックな修飾物質としてのアミド誘導体およびこれらの使用方法 |
| HRP20141094T1 (hr) * | 2008-07-08 | 2015-01-16 | Incyte Corporation | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze |
| NO2694640T3 (es) * | 2011-04-15 | 2018-03-17 | ||
| JP6313415B2 (ja) * | 2013-03-15 | 2018-04-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| AU2015239886B2 (en) * | 2014-04-04 | 2018-02-01 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| US11135221B2 (en) * | 2015-12-23 | 2021-10-05 | Moonshot Pharma Llc | Methods for inducing an immune response |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es not_active Application Discontinuation
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 MX MX2018015275A patent/MX382877B/es unknown
- 2017-05-31 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro not_active IP Right Cessation
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en not_active Ceased
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko not_active Expired - Fee Related
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190378A1 (es) | Compuestos de 2,3-dihidro-1h-indol | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| GB2552286A (en) | Polycrystalline diamond compact with gradient interfacial layer | |
| PH12019501029A1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor | |
| JO2794B1 (en) | Treatment of platinum resistant cancer | |
| PE20141061A1 (es) | Compuesto inhibidor de la senalizacion de la trayectoria notch | |
| PE20200785A1 (es) | Metodo para la preparacion de gas de sintesis | |
| AU2017260630A1 (en) | Detection of lung neoplasia by analysis of methylated DNA | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| MY201334A (en) | Method for the preparation of synthesis gas | |
| CL2016000466A1 (es) | Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. | |
| MX2019005310A (es) | Accesorio de iluminacion para cascos de soldadura. | |
| PH12019500459A1 (en) | Biosynthetic heparin | |
| UY29446A1 (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| CL2014003496A1 (es) | Compuestos profarmacos de rebamipida; su metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de ulcera gastrica, gastritis aguda y cronica, cancer, artritis reumatoide, diabetes, sindrome de colon irritable, entre otras enfermedades. | |
| MX2016005596A (es) | Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. | |
| CU23853B1 (es) | Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2 | |
| MX2020004034A (es) | Metodo de preparacion para un inhibidor de tirosina cinasa e intermediario del mismo. | |
| ES2551827A1 (es) | Equipo flotante para el aprovechamiento de la energía de las corrientes marinas | |
| ES2199086B1 (es) | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. | |
| MX2018015871A (es) | Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. | |
| TW201613928A (en) | Vinyl compounds as inhibitors for FGFR and VEGFR | |
| EA201692306A1 (ru) | Способ | |
| IN2013MU02010A (es) | ||
| NZ717669A (en) | Process of producing cycloalkylcarboxamido-indole compounds |